tiprankstipranks
Trending News
More News >
Scandinavian ChemoTech AB Class B (SE:CMOTEC.B)
:CMOTEC.B
Advertisement

Scandinavian ChemoTech AB Class B (CMOTEC.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Scandinavian ChemoTech AB Class B

(Frankfurt:CMOTEC.B)

Rating:54Neutral
Price Target:
Scandinavian ChemoTech AB shows strong revenue growth and has a solid financial structure with no debt, reducing financial risk. However, persistent operational inefficiencies and ongoing cash burn weigh on profitability and valuation. Technical indicators point to short-term momentum, but potential overbought conditions warrant caution. Overall, while there are promising aspects, significant challenges in achieving sustainable profitability remain.

Scandinavian ChemoTech AB Class B (CMOTEC.B) vs. iShares MSCI Sweden ETF (EWD)

Scandinavian ChemoTech AB Class B Business Overview & Revenue Model

Company DescriptionScandinavian ChemoTech AB Class B (CMOTEC.B) is a Swedish medical technology company that operates within the healthcare sector, focusing on developing innovative treatments for cancer. The company specializes in the research, development, and commercialization of tumor-specific electroporation techniques aimed at improving the effectiveness of cancer treatment. With a commitment to enhancing patient outcomes, Scandinavian ChemoTech provides advanced medical solutions that leverage cutting-edge technology to address unmet needs in oncology care.
How the Company Makes MoneyScandinavian ChemoTech AB generates revenue primarily through the sale and licensing of its proprietary medical technologies and devices designed for cancer treatment. The company's revenue streams include direct sales of its electroporation equipment to healthcare providers and hospitals, as well as potential licensing agreements with other medical technology companies. Additionally, Scandinavian ChemoTech may engage in strategic partnerships or collaborations that contribute to its earnings, leveraging its specialized expertise in electroporation to expand its market reach and enhance its product offerings. These revenue-generating activities are supported by ongoing research and development investments, aimed at continuously improving the efficacy and safety of their treatments.

Scandinavian ChemoTech AB Class B Financial Statement Overview

Summary
Scandinavian ChemoTech AB shows promising revenue growth but continues to face challenges with profitability and cash flow management. The company's financial structure benefits from a lack of debt, reducing financial risk, but operational improvements are needed to achieve sustainable profitability. Continued investment and strategic adjustments may be required to address ongoing losses and cash outflows.
Income Statement
45
Neutral
The company demonstrates significant revenue growth, with a sharp increase from SEK 473,000 in 2022 to SEK 6,566,000 in 2024. However, the company has consistently reported negative net income, resulting in negative net profit margins, indicating ongoing losses. Gross profit margins have improved, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.
Balance Sheet
55
Neutral
The balance sheet shows an improvement in the equity ratio, as stockholders' equity remains positive and there is no debt on the balance sheet as of 2024. The return on equity is negative due to persistent losses, but the absence of debt reduces financial risk. The company has a reasonable buffer of cash and short-term investments relative to its liabilities.
Cash Flow
50
Neutral
The company's free cash flow has improved from highly negative figures in previous years but remains negative, indicating ongoing cash burn. Operating cash flows have been negative, but financing activities have provided necessary liquidity. The cash flow to net income ratios are negative due to the negative net income and operating cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.57M2.82M473.00K49.00K131.00K
Gross Profit4.78M1.66M-55.00K323.00K-14.00K
EBITDA-10.73M-19.58M-20.81M-17.03M-10.77M
Net Income-13.72M-21.09M-24.58M-18.42M-12.50M
Balance Sheet
Total Assets13.38M14.87M21.70M25.81M15.99M
Cash, Cash Equivalents and Short-Term Investments949.00K923.00K5.85M8.68M1.49M
Total Debt0.000.000.0053.00K2.71M
Total Liabilities7.40M3.84M7.71M1.89M6.75M
Stockholders Equity5.98M11.03M13.99M23.92M9.24M
Cash Flow
Free Cash Flow-13.19M-18.91M-19.96M-22.36M-10.32M
Operating Cash Flow-13.14M-18.23M-19.63M-19.18M-8.49M
Investing Cash Flow-2.00K-468.00K-603.00K-3.33M-1.83M
Financing Cash Flow13.17M13.77M17.26M29.71M8.98M

Scandinavian ChemoTech AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.00
Price Trends
50DMA
1.99
Positive
100DMA
1.62
Positive
200DMA
1.62
Positive
Market Momentum
MACD
0.04
Negative
RSI
51.96
Neutral
STOCH
44.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CMOTEC.B, the sentiment is Positive. The current price of 2 is above the 20-day moving average (MA) of 1.90, above the 50-day MA of 1.99, and above the 200-day MA of 1.62, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 44.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CMOTEC.B.

Scandinavian ChemoTech AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
kr49.02M-236.60%132.67%58.89%
52
Neutral
$7.53B0.20-63.81%2.31%16.15%0.40%
34
Underperform
kr26.13M-105.54%63.82%
32
Underperform
€6.37M-209.54%97.86%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:CMOTEC.B
Scandinavian ChemoTech AB Class B
2.00
0.14
7.53%
SE:QUIA
QuiaPEG Pharmaceuticals Holding AB
0.01
-0.03
-72.22%
SE:STABL
Stayble Therapeutics AB
0.41
-0.26
-38.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025